Author Archives: yun

Congenital disorders

A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran

Posted on by yun
24
Jul

Objectives General objective Measuring safety of the booster doses of AstraZeneca vaccine in people vaccinated with two doses of Sinopharm or Sputnik V vaccines in Iran. Specific objectives 1) To Estimate the incidence of different types of serious adverse events (SAEs) within 13 weeks in all enrolled vaccinated individuals after either the first or second […]

Continue reading →
Blood

Research Reveals Blood Platelets Play Important Role in Kawasaki Disease

Posted on by yun
24
Jul

Newswise — LOS ANGELES (July 24, 2023) — Cedars-Sinai Guerin Children’s investigators have advanced our understanding of the role that blood platelets play in Kawasaki disease, a serious illness that primarily affects children younger than 5 years old and causes their blood vessels to swell. The findings, published in the peer-reviewed journal JCI Insight, may guide the […]

Continue reading →
Cancer and neoplasms

A network medicine approach to study comorbidities in heart failure with preserved ejection fraction

Posted on by yun
24
Jul

Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:401–10. Article  PubMed  Google Scholar  Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591–602. Article  PubMed  Google Scholar  Mishra S, Kass DA. Cellular and molecular pathobiology […]

Continue reading →
Infection

Understanding virus–host interactions in tissues

Posted on by yun
24
Jul

Abstract Although virus–host interactions are usually studied in a single cell type using in vitro assays in immortalized cell lines or isolated cell populations, it is important to remember that what is happening inside one infected cell does not translate to understanding how an infected cell behaves in a tissue, organ or whole organism. Infections […]

Continue reading →
Blood

Global Microtainer Blood Collection Market Set to Thrive at US$ 2.2 Billion by 2033

Posted on by yun

New York, July 24, 2023 (GLOBE NEWSWIRE) — The global microtainer blood collection market stood at US$ 1.1 billion in 2022 and is forecasted to expand at a CAGR of 6.6% from 2023 to 2033. Microtainers allow for a minimally intrusive blood collection process that is increasingly being preferred by healthcare professionals. Increased need for […]

Continue reading →
Blood

Gilead Drops Late-Stage Trial for Magrolimab in Blood Cancer Treatment

Posted on by yun
24
Jul

Pictured: Corporate headquarters of Gilead in Silicon Valley/iStock, Sundry Photography Gilead has discontinued the Phase III ENHANCE study of its investigational anti-CD47 antibody magrolimab for the treatment of patients with higher-risk myelodysplastic syndromes, the company announced Friday. The decision to end the study was triggered by a planned analysis of its data, which satisfied the […]

Continue reading →
Blood

Virginians May Now Indicate Their Blood Type on Their Driver’s License or ID

Posted on by yun
24
Jul

Virginians may indicate their blood type when they renew or replace their driver’s license or ID at dmv.virginia.gov or in-person at any Virginia Department of Motor Vehicles (DMV) customer service center, according to the DMV. “The law was intended to aid individuals and first responders when every second counts in an emergency,” said DMV Commissioner […]

Continue reading →
Cardiovascular

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

Posted on by yun

Partnership combines Roche’s proven track record of successfully developing and launching innovative medicines worldwide with Alnylam’s leadership in RNAi therapeutics Zilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressure Hypertension, the leading cause of cardiovascular disease, […]

Continue reading →